Trials, therapies, and evidence that changes care.
Europe PMC
Verdict: MajorRemibrutinib is a highly selective, potent, covalent, CNS-penetrant, oral BTK inhibitor.
In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss.
Sibeprenlimab, a humanized monoclonal antibody, selectively inhibits the cytokine A proliferation-inducing ligand (APRIL), a key driver of IgA nephropathy.
Retatrutide, an investigational triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, may be useful for treating obstructive ....
It remains unclear if intraoperative hemodynamic therapy should be guided by cardiac index.
Cardiovascular diseases (CVD) are the leading cause of global mortality, responsible for 17.8 million deaths and 423 million prevalent cases annually.
For patients with eosinophilic granulomatosis with polyangiitis (EGPA), guidelines recommend considering maintenance therapy after achieving remission.